Brandes Investment Partners’s Takeda Pharmaceutical TAK Stock Holding History

Brandes Investment Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$82.1M	Buy	4,430,642 +548,760	+14%	+$9.63M	0.58%	61
2025 Q4	$60.5M	Sell	3,881,882 -49,921	-1%	-$714K	0.46%	71
2025 Q3	$57.6M	Buy	3,931,803 +219,525	+6%	+$3.26M	0.46%	74
2025 Q2	$57.4M	Buy	3,712,278 +208,136	+6%	+$3.08M	0.52%	67
2025 Q1	$52.1M	Buy	3,504,142 +464,557	+15%	+$6.51M	0.53%	66
2024 Q4	$40.2M	Sell	3,039,585 -192,019	-6%	-$2.64M	0.45%	70
2024 Q3	$46M	Buy	3,231,604 +596,577	+23%	+$8.46M	0.52%	65
2024 Q2	$34M	Sell	2,635,027 -267,480	-9%	-$3.54M	0.42%	69
2024 Q1	$40.3M	Buy	2,902,507 +251,242	+9%	+$3.65M	0.52%	62
2023 Q4	$37.8M	Buy	2,651,265 +849,229	+47%	+$12M	0.57%	59
2023 Q3	$27.9M	Buy	1,802,036 +36,717	+2%	+$568K	0.54%	59
2023 Q2	$27.7M	Sell	1,765,319 -52,653	-3%	-$863K	0.56%	55
2023 Q1	$30M	Buy	1,817,972 +1,699,552	+1,435%	+$27.1M	0.64%	49
2022 Q4	$1.85M	Sell	118,420 -1,752,623	-94%	-$24.5M	0.05%	95
2022 Q3	$24.3M	Sell	1,871,043 -151,504	-7%	-$2.11M	0.63%	45
2022 Q2	$28.4M	Sell	2,022,547 -87,299	-4%	-$1.25M	0.69%	44
2022 Q1	$30.2M	Buy	2,109,846 +360,083	+21%	+$5.29M	0.65%	45
2021 Q4	$23.9M	Sell	1,749,763 -266,061	-13%	-$3.73M	0.52%	56
2021 Q3	$33M	Sell	2,015,824 -66,411	-3%	-$1.11M	0.72%	48
2021 Q2	$35M	Buy	2,082,235 +321,387	+18%	+$5.47M	0.78%	43
2021 Q1	$32.3M	Buy	1,760,848 +97,767	+6%	+$1.76M	0.76%	44
2020 Q4	$30.2M	Buy	1,663,081 +208,042	+14%	+$3.65M	0.78%	46
2020 Q3	$26M	Sell	1,455,039 -215,770	-13%	-$3.93M	0.9%	41
2020 Q2	$30M	Sell	1,670,809 -127,430	-7%	-$2.29M	0.91%	41
2020 Q1	$27.3M	Buy	1,798,239 +84,890	+5%	+$1.54M	0.96%	39
2019 Q4	$33.8M	Sell	1,713,349 -129,886	-7%	-$2.48M	0.8%	41
2019 Q3	$31.7M	Buy	1,843,235 +499,819	+37%	+$8.64M	0.82%	44
2019 Q2	$23.8M	Sell	1,343,416 -133,599	-9%	-$2.43M	0.53%	55
2019 Q1	$30.1M	Buy	1,477,015 +463,133	+46%	+$9.32M	0.7%	47
2018 Q4	$17.1M	Buy	+1,013,882	New	+$17.1M	0.43%	61

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Brandes Investment Partners's TAK Position: Q1 2026 in Review

Brandes Investment Partners increased its Takeda Pharmaceutical (TAK) stake by 14% in Q1 2026, buying an estimated $9.63M and bringing the position to 4,430,642 shares worth $82.1M. The position accounts for 0.58% of the portfolio, ranked #61.

Brandes Investment Partners first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Brandes Investment Partners held 4,430,642 shares of Takeda Pharmaceutical worth $82.1M as of Q1 2026.
Brandes Investment Partners bought 548,760 Takeda Pharmaceutical shares in Q1 2026, an estimated $9.63M.
Takeda Pharmaceutical made up 0.58% of Brandes Investment Partners's portfolio in Q1 2026, its #61 holding.
Brandes Investment Partners first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Brandes Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.